A

Metabolic Surgery Research

Anthropometry may help personalize bypassed bowel length

Sayadishahraki, Mahmoudieh, Keleidari, Melali, Heidary, Hosseini, Qane | Advanced Biomedical Research, 2023 | DOI source

Sayadishahraki and colleagues measured small bowel length intraoperatively in 150 patients undergoing abdominal operations and compared it with anthropometric variables. Mean length was 5.45 meters, shorter in women than men. Height correlated positively and the second-to-fourth finger ratio inversely. In the laparoscopic subgroup, age, weight, waist circumference, and right hemithorax length also tracked with length.

The point is not a finger-ratio calculator but a technical problem: fixed limb lengths ignore wide variation in total bowel length. That matters most when an operation adds malabsorption and the margin between weight loss and protein-calorie malnutrition narrows. The study is cross-sectional, single-region, and not limited to bariatric cases, so it should not drive limb-length decisions alone.

Extreme BMI is common in bariatric surgery and should not exclude care

Albaugh, Garcia Navas, Ross, Corpodean, Kachmar, Danos, Heymsfield, Katzmarzyk et al. | Obesity, 2026 | DOI source

Albaugh and colleagues analyzed 1,262,454 bariatric surgery patients from 2015 through 2023 to characterize BMI at or above 60 kg/m2, including beyond 80. Some 5.3% had BMI at or above 60 and about 1.1% at or above 70 each year. Higher strata carried more comorbidity and complication risk, but absolute rates stayed low: in the BMI 70-plus group, serious complications were 2.57% and mortality 0.35%.

This gives programs a national denominator for a group usually discussed in anecdotes. These patients need equipment, anesthesia planning, ICU availability, VTE mitigation, and surveillance, but the data argue against BMI alone as a gatekeeper. The patients with the greatest disease burden are the easiest to label too high risk. The take-home is risk stratification, not risk avoidance.

MBSAQIP data show falling volumes and rising complexity

Wills, Zhu, Elamin, Corcelles, Kroh, Dang, Strong, Navarrete, Mocanu | Obesity Surgery, 2026 | DOI source

Wills and colleagues reviewed 1,006,270 MBSAQIP procedures from 2020 through 2024. Annual volume rose to 230,707 cases in 2022, then fell to 177,789 in 2024, a 23% decline from peak. Conversions rose from 8.9% to 11.0% as primary procedures shrank as a share. Sleeve gastrectomy declined modestly, RYGB increased, ASA class III or higher became more common, and serious complications still fell from 3.39% to 3.10%.

This is a workforce and access paper as much as an outcomes paper. Lower volume with more conversions and sicker patients changes OR planning, fellowship exposure, staffing, and benchmarking. The registry cannot prove GLP-1 drugs caused the decline, and COVID-era disruption remains background. Programs should defend access while adapting to patients arriving later and more complex.

Same-day discharge evidence is too heterogeneous to pool

Hany, Torensma, Ragab, Abouelnasr, Bos, Ikram, Aarts, Berends | Obesity Surgery, 2026 | DOI source

Hany and colleagues reviewed 41 same-day discharge studies in bariatric surgery representing 1,953,247 patients. The finding was methodological heterogeneity rather than a pooled estimate: 95% of studies used unique inclusion definitions, 94% unique exclusions, and every study with discharge criteria used a unique definition. Reported success ranged from 63% to 100%, and readmission, leak, and mortality data could not be pooled reliably.

Programs should not treat published same-day discharge rates as plug-and-play evidence. A protocol that works after sleeve gastrectomy in a narrow population may not translate to RYGB, higher ASA status, long travel, or limited home support. A differential safety signal driven largely by RYGB data is hypothesis-generating. The selection and discharge rules are the intervention.

B

Science of Obesity Metabolism

Network meta-analysis compares GLP-1 based drugs in adults without diabetes

Chen, Ma, Sun, Zhang, Gong, Wang, Liu, Zha et al. | BMJ Medicine, 2026 | DOI source

Chen and colleagues performed a network meta-analysis of randomized trials comparing GLP-1 based medications for weight loss in adults with overweight or obesity without diabetes. The design allows indirect comparison across agents and doses while head-to-head obesity trials remain limited, and it addresses safety as well as efficacy, since tolerability and discontinuation shape real-world persistence.

The paper frames the medication discussion that now precedes many surgical consults. Patients arrive having tried one incretin, lost coverage, or asking whether a different drug avoids surgery. Network meta-analysis informs that conversation but cannot replace direct comparative trials or individual assessment of contraindications, prior response, cost, and adherence.

Composite cardiometabolic ranking favors higher-dose semaglutide and orforglipron

Lu, Chen, Guo, Ding, Liu, Van Name, Sharifi, Lu, Chen | Diabetes, Obesity and Metabolism, 2026 | DOI source

Lu and colleagues reviewed 19 randomized trials including 13,117 adults with overweight or obesity, comparing GLP-1 mono-agonists on an index combining weight loss, triglycerides, HDL-C, LDL-C, waist circumference, HbA1c, and systolic blood pressure. Semaglutide 7.2 mg ranked highest at 0.86, then orforglipron 36 mg at 0.68 and semaglutide 2.4 mg at 0.66. Rankings were similar in diabetes and non-diabetes subgroups.

The useful part is the multidimensional frame. Patients rarely care only about weight, and surgeons see histories of dose escalation, oral options, intolerance, or partial response. A composite index sharpens discussion but compresses different outcomes into one score across trials with different populations and follow-up. Use it as a selection frame, not a substitute for patient-level risk.

VA/DoD guideline treats obesity as chronic longitudinal care

Corrado, Raffa, Bauer, Eisenberg, Weare-Regales, Antonovich, Loblack et al. | Annals of Internal Medicine, 2026 | DOI source

Corrado and colleagues summarize the 2025 VA and Department of Defense guideline for adult overweight and obesity. The panel reviewed evidence from April 2019 through January 2025 and frames obesity as a chronic, relapsing disease needing longitudinal treatment. It recommends BMI screening in clinical context, with lifestyle intervention foundational and medications, endoscopic therapy, and surgery integrated when indicated.

The surgical relevance is direct: the guideline places bariatric procedures inside a continuum rather than at the end of failed dieting. That supports earlier referral, shared care with primary care and obesity medicine, and continued treatment after surgery. Use the language to support access, not to add preoperative hurdles.

Gallup reports GLP-1 use at 11% of U.S. adults

Dan Witters | Gallup, 2026 | Source ↗

Gallup reports 11% of U.S. adults currently take GLP-1 medications for weight loss, up from 3% in 2024, with 15% having used them at some point. The data come from the Gallup National Health and Well-Being Index, a probability-based web survey of 5,065 adults conducted May 28 to June 5, 2026. Self-reported adult obesity fell from a 39.9% peak in 2022 to 36.4% in 2026. Brand-name products were 68% of current use; 19% reported compounded versions.

This is a survey, not proof that GLP-1 adoption caused a national obesity decline. Self-reported height, weight, and medication use carry known limits, and the compounded market adds uncertainty. Still, the scale of reported use changes the background for bariatric practice: expect more patients who used incretins, switched for cost, or formed expectations before evaluation.

C

Metabolic Innovation and Technology

Patients want transparency and control when AI enters care

Cailey Gleeson | Fierce Healthcare, 2026 | Source ↗

Fierce Healthcare reports on a Pew Research Center survey of 3,488 U.S. adults about artificial intelligence in healthcare. Fifty-three percent said they had little or no control over AI use in their care, and 63% wanted more say. Nearly half were unsure whether AI had been used at all. Disclosure mattered: 72% called it very or extremely important for providers to say when AI is used.

Bariatric programs will use AI first in the quiet parts of care: documentation, scheduling, education, prior authorization, triage, and follow-up. Those uses still affect trust where patients face stigma and fragmented access. Tell patients when AI touches care decisions, explain what the clinician reviews, and define how to reach a human.

Doximity report links physician compensation, workload, and AI adoption

Doximity | Doximity, 2026 | Source ↗

Doximity's 2026 compensation report combines survey data, workforce signals, recruiting activity, and polls on workload and AI, drawing on roughly 250,000 responses over seven years including nearly 23,000 U.S. physicians surveyed in 2025. Average compensation rose 2% from 2024 to 2025, slower than the prior year. It also covers specialty and metro variation, locum tenens demand, autonomy concerns, and expectations around clinical AI.

For bariatric surgeons this is not a salary table. It captures operational pressure: staffing strain, administrative load, uneven regional economics, and rapid experimentation with AI meant to recover time. General surgery sits among higher-compensated specialties, but cost of living and practice structure matter. Tools will be judged on whether they cut workload without adding liability.

Coordinated obesity teams are moving from ideal to operating model

Giuliana Grossi | The American Journal of Managed Care, 2026 | Source ↗

AJMC reports on a New York roundtable where obesity care leaders discussed fragmented access, insurance-driven prescribing, multidisciplinary care, and technology-enabled follow-up, including AI-assisted prior authorization and agentic follow-up calls for adverse-effect monitoring. The format is expert discussion and reporting, not a comparative outcomes study.

It still speaks to a daily problem: patients need coordinated care before, during, and after treatment. Programs depend on dietitians, behavioral health, obesity medicine, primary care, pharmacy, and administration, but handoffs are brittle. Automation may help if it reduces friction and catches problems earlier, and may worsen inequity if it adds another opaque layer.

AI-designed drugs expose an inventorship gap

Regalado | MIT Technology Review, 2026 | Source ↗

MIT Technology Review examines the legal problem when AI systems help design drug candidates. U.S. patent law names human individuals as inventors, reinforced by the DABUS litigation and later guidance. The article uses AI drug-development companies, including Insilico Medicine, to show the mismatch between public claims about AI discovery and filings listing human inventors. The USPTO recognizes the issue but still treats AI as a tool.

This may feel distant from bariatric surgery, but it will affect the metabolic pipeline. If AI accelerates obesity, MASH, addiction, and cardiometabolic discovery, ownership and patent validity will influence investment, pricing, and access. The clinical question is whether incentives produce useful drugs patients can actually obtain.

D

Metabolic Marketplace

FDA adds cardiovascular-risk reduction to Mounjaro label

Eli Lilly and Company | Eli Lilly and Company / PRNewswire, 2026 | Company release

Eli Lilly announced FDA approval of tirzepatide to reduce major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. The decision rests on SURPASS-CVOT, comparing tirzepatide with dulaglutide in 13,299 participants across 30 countries. Tirzepatide met noninferiority, with an observed 8% lower rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Superiority was not established.

The label expansion strengthens cardiometabolic framing for incretins in diabetes but does not make medication and surgery interchangeable. Many surgical candidates have cardiovascular disease, diabetes, severe obesity, or all three, and need sequencing that weighs risk reduction, weight loss, glycemic control, durability, and access. The comparator matters because dulaglutide already has cardiovascular evidence.

Prime Therapeutics maps the next GLP-1 pipeline decisions

Prime Therapeutics editorial team | Prime Therapeutics, 2026 | Source ↗

Prime Therapeutics' August 2026 pipeline update summarizes the expanding GLP-1 market across oral products, high-dose formulations, combination therapy, and new indications. It lists 2026 decision points including tirzepatide for cardiovascular risk reduction, oral orforglipron for type 2 diabetes, oral semaglutide 25 mg, and fixed-dose semaglutide plus cagrilintide for weight loss. It is a PBM-produced overview, not independent clinical evidence.

Read pipeline reports for what they reveal about payer behavior and patient expectations. Oral agents and combination injectables may raise demand, shift referral timing, and intensify prior authorization battles. The cagrilintide story keeps lean mass, tolerability, and maintenance in view. Patients compare surgery against a moving drug market, not a static standard.

Reuters tracks weight-loss drugs across new indications

Reuters | Reuters, 2026 | Source ↗

Reuters updates its roundup of GLP-1 development beyond weight loss, spanning cardiovascular risk, MASH, obstructive sleep apnea, osteoarthritis, alcohol use disorder, Alzheimer disease, and other areas where obesity biology overlaps with inflammation, metabolism, reward, and mechanical load. It is a market and pipeline overview, not a new efficacy trial.

Broader indications complicate referral conversations. A patient may start an incretin for diabetes, sleep apnea, liver disease, or weight loss, then reach surgery after partial response, intolerance, cost barriers, or regain. Expansion may help payers treat obesity as disease modification rather than cosmetic. The counterweight is hype: each indication needs its own evidence.

Boston Scientific cyber incident disrupts order processing

Boston Scientific | Boston Scientific, 2026 | Company update

Boston Scientific disclosed a cybersecurity incident identified on August 25 affecting certain information technology systems. The company said it caused a network outage and disrupted operations, including access to business applications used to process and ship customer orders. It activated incident response protocols, began an investigation, and engaged outside cybersecurity experts. The timeline for full restoration was not known.

This is not a bariatric-device story in the narrow sense, but it matters to any operating room dependent on medtech supply chains. Cyber events can affect ordering, implant availability, loaner instruments, and case scheduling even when patient data are not central. Know which supplies have single-vendor dependencies and who monitors disruptions.